MONTREAL, May 31, 2022 /CNW Telbec/ - Innodem Neurosciences, a leading provider of innovation and technology for the convergence of neurosciences, digital health, pharmaceutical and artificial intelligence, is proud to announce that its novel mobile eye...
MONTREAL, Oct. 5, 2021 /PRNewswire/ - Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with...
Innodem Neurosciences, a Montreal-based company, has closed a Series A financing round led by Morningside Ventures to support the development and commercialization of its proprietary, patented, digital biomarking technology of neurodegenerative diseases such as...
Patients who have lost the use of speech will soon be able to communicate with their eyes thanks to a mobile application developed in Quebec. Called Pigio™, the application will allow communication with the eyes, which act as a cursor on a digital screen. "You have...
Montreal-based Innodem Neurosciences has received $1 million from angel, banking, and government entities to begin commercializing Pigio™, its first mobile app. Pigio™ uses AI-powered mobile software technology to allow paralyzed or intubated patients to communicate...
Dr. de Villers-Sidani was amongst the three McGill researchers presented their work to the World Economic Forum’s (WEF) Annual Meeting of the New Champions (a.k.a. “Summer Davos”) on September 18, in Tianjin, China. It’s the foremost global summit on...
CENTECH, a Montreal-based technology incubator, announced earlier that it has selected a company founded by Dr. Etienne de Villers-Sidani for its Propulsion Program, which helps the most innovative start-ups move from the initial development phase to commercializing...